Provided herein are ionic self-assembling peptides, pharmaceutical compositions comprising the peptides, and methods of using and making the same.

Provided herein are ionic self-assembling peptides, pharmaceutical compositions comprising the peptides, and methods of using and making the same.

Disclosed is a composition for promoting biosynthesis of elastin or collagen. The composition improves the ability of fibroblasts to biosynthesize elastin and collagen and is thus used to restore skin elasticity deteriorated due to aging or light exposure, remove wrinkles and facial lines, improve vascular elasticity deteriorated due to aging, and hypertension and decreased blood circulation caused thereby, and enhance tendon and ligament elasticity and joint elasticity.

The present disclosure relates to compositions and methods for treating a dysregulated wound healing, for improving wound healing, for inhibiting scar formation, for treating a subject with Ehlers Danlos syndrome (EDS), and for treating a subject diagnosed with a heart attack. The present disclosure further relates to compositions and methods for predicting future cardiac risk in a subject who has suffered a heart attack, and predicting risk of future cardiac disease in a subject suffering a heart attack.

The present disclosure relates to compositions and methods for treating a dysregulated wound healing, for improving wound healing, for inhibiting scar formation, for treating a subject with Ehlers Danlos syndrome (EDS), and for treating a subject diagnosed with a heart attack. The present disclosure further relates to compositions and methods for predicting future cardiac risk in a subject who has suffered a heart attack, and predicting risk of future cardiac disease in a subject suffering a heart attack.

The present invention relates to novel Collagen I translation inhibitors, composition and methods of preparation thereof, and uses thereof for treating Fibrosis including lung, liver, kidney, cardiac and dermal fibrosis, IPF, wound healing, scarring and Gingival fibromatosis, Systemic Sclerosis, and alcoholic and non-alcoholic steatohepatitis (NASH).

A use of a FAK inhibitor in the preparation of a drug for preventing and/or treating tumors having an NRAS mutation. A method for treating tumors that have experienced an NRAS mutation, which comprises administering an effective dose of a FAK inhibitor to an individual. A FAK inhibitor for treating tumors having an NRAS mutation. The FAK inhibitor is BI853520, defactinib, GSK2256098, PF-00562271, VS-4718 or a pharmaceutically acceptable salt thereof.

A use of a FAK inhibitor in the preparation of a drug for preventing and/or treating tumors having an NRAS mutation. A method for treating tumors that have experienced an NRAS mutation, which comprises administering an effective dose of a FAK inhibitor to an individual. A FAK inhibitor for treating tumors having an NRAS mutation. The FAK inhibitor is BI853520, defactinib, GSK2256098, PF-00562271, VS-4718 or a pharmaceutically acceptable salt thereof.

A method of producing an autologous anti-inflammatory/anti-catabolic autologous composition useful in the treatment of a mammal suffering from damaged and/or injured connective tissues, chronic tendinosis, chronic muscle tears, chronic degenerative joint conditions, and/or skin inflammatory disorders is provided. The method comprising the following steps: delivering a blood collected from the mammal to a tube; storing the blood in presence of sodium citrate at a temperature of from about 20° C. to about 40° C. for at least about 3.5 hours; centrifuging the blood to separate the blood into a supernatant component and a cellular fraction; and collecting the supernatant component.

This invention provides compounds of Formula I

##STR00001##

wherein B, G, A, E, R.sup.1, R.sup.2, R.sup.3, m and n are as defined herein, which are useful as type I receptor tyrosine kinase inhibitors, and methods of use thereof in the treatment of hyperproliferative disorders in mammals.